Study identifier:D1441C09907
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Quetiapine augmentation to SRIs for patients with obsessive compulsive disorder, a double-blind, placebo-controlled study
Obsessive Compulsive Disorder
Phase 2
No
Quetiapine
All
90
Interventional
18 Years - 70 Years
Allocation: Randomized 
Endpoint Classification: Efficacy Study 
Intervention Model: Parallel Assignment 
Masking: Double Blind 
Primary Purpose: Treatment 
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
| Arms | Assigned Interventions | 
|---|